Anti Mog, IgG-Nmo Antibody and Disability in Patients with Neuromyelitis Optica

Abstract

Background: Neuromyelitis optica (NMO) is a clinically defined entity within the spectrum of inflammatory demyelinating diseases of the central nervous system (CNS) which is characterized by inflammatory attacks that are confined to the spinal cord and the optic nerves. The finding of anti-aquaporin-4 (AQP4) antibodies in the majority of patients with NMO has advanced pathogenic understanding of the disease. Recent evidence suggests that some of the NMO cases are related to antibodies against myelin oligodendrocyte glycoprotein (MOG).